Addex Therapeutics Ltd

Company Profile

Addex Therapeutics Ltd had its IPO on 2020-01-29 under the ticker symbol ADXN.

The company operates in the Healthcare sector and Biotechnology industry. Addex Therapeutics Ltd has a staff strength of 26 employees.

Stock update

Shares of Addex Therapeutics Ltd opened at $0.7 at the start of the last trading session i.e. 2023-06-02.

The stocks traded within a range of $0.68 - $0.7, and closed at $0.7.

This is a +0.13% increase from the previous day's closing price.

A total volume of 59,128 shares were traded at the close of the day’s session.

In the last one week, shares of Addex Therapeutics Ltd have slipped by -4.12%.

Addex Therapeutics Ltd's Key Ratios

Addex Therapeutics Ltd has a market cap of $34.19 million, indicating a price to book ratio of 1.4085 and a price to sales ratio of 10.2796.

In the last 12-months Addex Therapeutics Ltd’s revenue was $1.25 million with a gross profit of $-9687235 and an EBITDA of $-21509952. The EBITDA ratio measures Addex Therapeutics Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Addex Therapeutics Ltd’s operating margin was -1707.44% while its return on assets stood at -87.86% with a return of equity of -202.67%.

In Q3, Addex Therapeutics Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a negative 45.1%.

Addex Therapeutics Ltd’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-2.56 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Addex Therapeutics Ltd’s profitability.

Addex Therapeutics Ltd stock is trading at a EV to sales ratio of 2.5393 and a EV to EBITDA ratio of -0.1471. Its price to sales ratio in the trailing 12-months stood at 10.2796.

Addex Therapeutics Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$12.24 million

Total Liabilities

$4.13 million

Operating Cash Flow

$2981.00

Capital Expenditure

$580

Dividend Payout Ratio

0%

Addex Therapeutics Ltd ended 2023 with $12.24 million in total assets and $0 in total liabilities. Its intangible assets were valued at $12.24 million while shareholder equity stood at $7.95 million.

Addex Therapeutics Ltd ended 2023 with $0 in deferred long-term liabilities, $4.13 million in other current liabilities, 652730.00 in common stock, $-346210419.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.42 million and cash and short-term investments were $10.43 million. The company’s total short-term debt was $285,922 while long-term debt stood at $0.

Addex Therapeutics Ltd’s total current assets stands at $11.70 million while long-term investments were $0 and short-term investments were $3085.00. Its net receivables were $457039.00 compared to accounts payable of $2.99 million and inventory worth $0.

In 2023, Addex Therapeutics Ltd's operating cash flow was $2981.00 while its capital expenditure stood at $580.

Comparatively, Addex Therapeutics Ltd paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$0.7

52-Week High

$5.45

52-Week Low

$0.55

Analyst Target Price

$

Addex Therapeutics Ltd stock is currently trading at $0.7 per share. It touched a 52-week high of $5.45 and a 52-week low of $5.45. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.8 and 200-day moving average was $0.95 The short ratio stood at 0.43 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 2074.3% are held by institutions.